7,250
-0.55%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Chabiotech Co
Its shares trade on KOSDAQ under the ticker 085660.KQ. It has been listed since 27 December 2005. In the fiscal year to 31 December 2025, it reported revenue of ₩1.27trn and a net loss of ₩109.88bn. At that date it held total assets of ₩2.55trn and shareholders' equity of ₩304.61bn.
Cha Biotech Co., Ltd. engages in the research of cell therapy and storage of cord blood. The company is headquartered in Seoul, Seoul. The company went IPO on 2005-12-27. is a Korea-based company mainly engaged in the bio business. Along with its subsidiaries, the Company operates its business through two segments: bio segment and optical segment. Its bio segment engages in the provision of medical services; development of stem cells and cell therapy products; production of cosmetics and cosmetic raw materials; distribution of medical devices and others, as well as cord blood storage, health care services and others. Its optical segment engages in the manufacture of optical lenses, optical modules and other parts, which are used in mobile phone cameras.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 27 Dec 2005
- Website
- chabio.com ↗
Leadership
Pay as last reported
- Gyu Beom HanCo-President
- Hyeong Min JungCo-President, since 2009
- Sang Hun OhChief Executive Officer, Director, since 2019
- Byeong Wu MoonVice Chairman of the Board, since 2009
- Gyeong Wuk YoonVice President, Director, since 2009
- Jong Guk SongManaging Director, since 2009
- Jin Hwan KimAssistant Managing Director
- Yeong Han KimAssistant Managing Director
- Sang Won LeeAssistant Managing Director
- Jeong Rim NamAssistant Managing Director
- Yin Su ParkInternal Auditor
- Byeong Geun SongAssistant Managing Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Chabiotech's bio segment focuses on stem cell therapy and cord blood storage in Seoul.
- The company's optical segment produces lenses for mobile phone cameras in Korea.
- Chabiotech operates two segments: bio and optical with diverse product offerings.
Weaknesses
- The bio segment's medical services face competition in the Korean Health Care sector.
- Optical segment's mobile phone camera parts face market saturation in Korea.
- Limited financial data available for Chabiotech's performance metrics.
Opportunities
- Growth in cord blood storage services within the Korean Health Care market.
- Expansion of stem cell therapy products in the global Health Care industry.
- Increasing demand for optical lenses in mobile phone manufacturing globally.
Threats
- Regulatory changes in the Korean Health Care sector affecting bio segment operations.
- Intensifying competition in the Korean optical components market.
- Economic downturns impacting global mobile phone manufacturing demand.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.